A New Approach to Prevent the Progression of Frailty in Prefrail Elderly Individuals through Agarooligosaccharide Intervention (Second Phase)

A New Approach to Prevent the Progression of Frailty in Prefrail Elderly Individuals through Agarooligosaccharide Intervention (Second Phase):Randomized Clinical Trial - Second Phase of the Clinical Trial to Inhibit the Progression of Prefrailty

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000055055

Enrollment

Registered

2024-07-24

Start date

2024-07-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prefrailty or frailty

Interventions

Taking 500mg/day of Agarooligosaccharide for 12 weeks Taking Placebo for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: "Individuals scoring 4 or more points on the 25-item frailty checklist"

Exclusion criteria

Exclusion criteria: People with high blood pressure

Design outcomes

Primary

Measure	Time frame
10 meter walking test	—

Secondary

Measure	Time frame
Taking 500mg/day AOSs or Placebo for 12 weeks 10-meter walking speed 30-second chair stand test Timed Up and Go test Lower limb muscle strength Grip strength Blood pressure Pain score	—

Countries

Japan

Contacts

Public ContactRYOJI HIROTA

Matsumoo university Department of Nutrition

ryoryo2003@yahoo.co.jp09036969547

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026